Abelacimab, formerly known as MAA868, represents a groundbreaking approach to managing thrombosis. This blood-thinning agent is a targeted monoclonal immunoglobulin that inhibits the integrin αIIbβ3, a key player in https://www.targetmol.com/compound/abelacimab